ArticleArchives of toxicology2026
Comparative toxicity of plant protection products, their active substances and mixtures in zebrafish embryos and HepaRG cells.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intensive use of plant protection products (PPPs) is essential in modern agriculture to ensure food security. PPPs are complex formulations of active substances (ASs) and co-formulants, yet regulatory risk assessment primarily focuses on AS toxicity, often overlooking combined effects. This study assessed the toxicity of three commercial PPPs, their AS-mixtures, and a co-formulant using the in vitro HepaRG liver cell assay and the in vivo zebrafish embryo toxicity test (ZFET). Product 1 contained the AS Benzovindiflupyr (Benzo), and Product 2 contained Benzo and Prothioconazole (Pro). Product 3 contained Pro and Tebuconazole (Teb) and the co-formulant N,N-Dimethyldecanamide (DDA), which was singled out for further investigation. AS were tested in different concentration ranges from 0.03 to 105 µmol/L in the ZFET and from 12.8 to 454.8 µmol/L in HepaRG cells. AS-mixtures were tested from 0.06 to 50 µmol AS/L (ZFET) and from 7.7 to 312.0 µmol AS/L (HepaRG). PPPs were tested from 0.02 to 29.8 µmol AS/L (ZFET) and from 2.9 to 312.0 µmol AS/L (HepaRG). PPPs were either more or as toxic as their respective AS-mixtures. In the ZFET, Products 1 and 2 showed similar toxicity to their AS-mixtures, while Product 3 showed a fourfold increase. In HepaRG cells, Product 1 was four times and Product 3 three times more toxic than their mixtures. Concentration addition models underestimated observed effects, particularly for Product 3, where co-formulants increased internal AS concentrations in zebrafish embryos. These findings underscore the need for whole mixture-based risk assessment for selected PPPs and support using integrated in vitro/in vivo approaches. Our study highlights the need for holistic PPP evaluation to improve safety assessments and regulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.